ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Gonadotropin-Releasing Hormone

Also written as “GnRH iontophoretic transdermal Lutrepatch”, “Luteinizing Hormone-Releasing Hormone (LHRH) Agonists” and “Lutrepulse”.

Its studies are mostly in Amenorrhea · Infertility · Ovarian Neoplasms, led by 2 companies.

Drug pageGonadotropin-Releasing Hormone: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 23, 20065 company-led studies, 1 open or runningNext primary completion: Feb 28, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ferring Pharmaceuticals40 open or runningphase 3since Feb 23, 2006Feb 23, 2006none ahead
Hoffmann-La Rocheits history only11 open or runningphase 2since Jun 9, 2021Jun 9, 2021Feb 28, 2028phase 2 · NCT04931342

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ferring Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 23, 2006First study: phase 3 study in InfertilityFirst studyNCT00296465 · 132 enrolled · United States
  2. Nov 20, 2008Phase 2 study in InfertilityNCT00796289 · 350 enrolled · United States
  3. Oct 15, 2013Phase 3 study in Primary Amenorrhea With Hypogonadotropic HypogonadismNCT01976728 · 39 enrolled · United States, Canada
  4. Aug 26, 2025Phase 1 study in AmenorrheaNCT07152730 · United States

TargetBeta

GNRHR →read by rule
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on GNRHR

ProgramCompanyFurthest phaseStudies
LeuprolideruleTakedaphase 439
triptorelinruleIpsenphase 421
GoserelinruleAstraZenecaphase 414
linzagolixruleKissei Pharmaceuticalphase 314
GnRH Antagonist SHR7280Jiangsu HengRui Medicinephase 310
leuprolide mesylateruleforesee-pharmaceuticals-co-ltdphase 33

Studies

All 4 Ferring Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07152730Amenorrhea · United States1WithdrawnOct 29, 20250
NCT01976728Primary Amenorrhea With Hypogonadotropic Hypogonadism · United States, Canada3CompletedFeb 23, 201839
NCT00796289Infertility · United States2CompletedDec 2009350
NCT00296465Infertility · United States3CompletedNov 2005132

How it is read

Names in the registry

  • “GnRH iontophoretic transdermal Lutrepatch”, 3 entries
  • “Luteinizing Hormone-Releasing Hormone (LHRH) Agonists”, 1 entry
  • “Lutrepulse”, 1 entry
  • “Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump”, 1 entry
  • “Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.